Cargando…

Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women

BACKGROUND: Pregnancy increases the risk of tuberculosis and its complications. A 3-month regimen of weekly isoniazid and rifapentine (3HP) is safe and effective for tuberculosis prevention in adults and children, including those with HIV, but 3HP has not been evaluated in pregnancy. METHODS: IMPAAC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mathad, Jyoti S, Savic, Rada, Britto, Paula, Jayachandran, Priya, Wiesner, Lubbe, Montepiedra, Grace, Norman, Jennifer, Zhang, Nan, Townley, Ellen, Chakhtoura, Nahida, Bradford, Sarah, Patil, Sandesh, Popson, Stephanie, Chipato, Tsungai, Rouzier, Vanessa, Langat, Deborah, Chalermchockcharoentkit, Amphan, Kamthunzi, Portia, Gupta, Amita, Dooley, Kelly E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Major Articles and Commentaries
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9070820/ https://www.ncbi.nlm.nih.gov/pubmed/34323955 http://dx.doi.org/10.1093/cid/ciab665

Ejemplares similares

Validation and application of a quantitative liquid chromatography tandem mass spectrometry assay for the analysis of rifapentine and 25-O-desacetyl rifapentine in human milk
por: Mkhize, Buyisile, et al.
Publicado: (2022)

Individual and Composite Adverse Pregnancy Outcomes in a Randomized Trial on Isoniazid Preventative Therapy Among Women Living With Human Immunodeficiency Virus
por: Theron, Gerhard, et al.
Publicado: (2020)

Pharmacokinetics and Drug‐Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping
por: Gausi, Kamunkhwala, et al.
Publicado: (2020)

Cost‐effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda
por: Ferguson, Olivia, et al.
Publicado: (2020)

Retraction: Isoniazid and Rifapentine Treatment Eradicates Persistent Mycobacterium tuberculosis in Macaques
Publicado: (2021)

Cost effectiveness of three months of rifapentine and isoniazid for latent tuberculosis in Syrian refugees
por: Ilaiwy, Ghassan, et al.
Publicado: (2021)

Cost-effectiveness analysis of 3 months of weekly rifapentine and isoniazid compared to isoniazid monotherapy in a Canadian arctic setting
por: Pease, Christopher, et al.
Publicado: (2021)

Isoniazid and rifapentine treatment effectively reduces persistent M. tuberculosis infection in macaque lungs
por: Sharan, Riti, et al.
Publicado: (2022)

Cost of Delivering 12-Dose Isoniazid and Rifapentine Versus 6 Months of Isoniazid for Tuberculosis Infection in a High-Burden Setting
por: Yuen, Courtney M, et al.
Publicado: (2020)

Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review
por: Lai, Wendy A., et al.
Publicado: (2022)

Safety & Benefits of Directly Observed Therapy with Rifapentine and Isoniazid for Latent Tuberculosis Infection – Less is More?
por: Ha, Lawrence, et al.
Publicado: (2017)

Rifapentine and isoniazid for prevention of tuberculosis in people with diabetes (PROTID): protocol for a randomised controlled trial
por: Ntinginya, Nyanda Elias, et al.
Publicado: (2022)

Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection
por: Borisov, Andrey S., et al.
Publicado: (2018)

Twice‐Daily Doravirine Overcomes the Interaction Effect from Once‐Weekly Rifapentine and Isoniazid in Healthy Volunteers
por: Lam, Edwin, et al.
Publicado: (2020)

Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine
por: McClintock, Adelaide H., et al.
Publicado: (2017)

Completion Rate and Side-Effect Profile of Three-Month Isoniazid and Rifapentine Treatment for Latent Tuberculosis Infection in an Urban County Jail
por: Juarez-Reyes, Maria, et al.
Publicado: (2016)

Using Video Technology to Increase Treatment Completion for Patients With Latent Tuberculosis Infection on 3-Month Isoniazid and Rifapentine: An Implementation Study
por: Lam, Chee Kin, et al.
Publicado: (2018)

Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis
por: Yu, Ya-Yen, et al.
Publicado: (2019)

Transmission of Mycobacterium tuberculosis in a High School and School-Based Supervision of an Isoniazid-Rifapentine Regimen for Preventing Tuberculosis — Colorado, 2011–2012
por: Bargman, Carolyn, et al.
Publicado: (2013)

Treatment of latent Mycobacterium tuberculosis infection with 12 once weekly directly-observed doses of isoniazid and rifapentine among persons experiencing homelessness
por: Nwana, Nwabunie, et al.
Publicado: (2019)

High rate of completion for weekly rifapentine plus isoniazid treatment in Chinese children with latent tuberculosis infection—A single center study
por: Yang, Heng, et al.
Publicado: (2021)

Plasma Concentrations of sTREM-1 as Markers for Systemic Adverse Reactions in Subjects Treated With Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection
por: Wang, Tsai-Yu, et al.
Publicado: (2022)

The implementation of rifapentine and isoniazid (3HP) in two remote Arctic communities with a predominantly Inuit population, the Taima TB 3HP study
por: Alvarez, G. G., et al.
Publicado: (2020)

Short‐course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide
por: Liou, Bo‐Huang, et al.
Publicado: (2021)

A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine
por: Francis, Jose, et al.
Publicado: (2019)

Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug
por: Svensson, Elin M., et al.
Publicado: (2015)

Activities of Rifampin, Rifapentine and Clarithromycin Alone and in Combination against Mycobacterium ulcerans Disease in Mice
por: Almeida, Deepak, et al.
Publicado: (2011)

HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients
por: Rockwood, Neesha, et al.
Publicado: (2016)

Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses
por: Pease, Christopher, et al.
Publicado: (2017)

Treating latent tuberculosis infection (LTBI) with isoniazid and rifapentine (3HP) in an inner-city population with psychosocial barriers to treatment adherence: A qualitative descriptive study
por: Heyd, Amber, et al.
Publicado: (2021)

Rifapentine-Proliposomes for Inhalation: In Vitro and In Vivo Toxicity
por: Patil-Gadhe, Arpana A., et al.
Publicado: (2014)

Simplifying Rifapentine Dosing for Tuberculosis Treatment and Prevention
por: Podany, Anthony T.
Publicado: (2020)

Completion of isoniazid–rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness–implementation randomized trial
por: Semitala, Fred C., et al.
Publicado: (2021)

Effect of pregnancy versus postpartum maternal isoniazid preventive therapy on infant growth in HIV-exposed uninfected infants: a post-hoc analysis of the TB APPRISE trial
por: Cherkos, Ashenafi S., et al.
Publicado: (2023)

Treatment of cervical cancer in HIV-seropositive women from developing countries: a protocol for a systematic review
por: Mapanga, Witness, et al.
Publicado: (2018)

Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania
por: Denti, Paolo, et al.
Publicado: (2015)

Estimating abortion incidence and unintended pregnancy among adolescents in Zimbabwe, 2016: a cross-sectional study
por: Riley, Taylor, et al.
Publicado: (2020)

Copper intrauterine device use and HIV acquisition in women: a systematic review
por: Hannaford, Philip C, et al.
Publicado: (2020)

Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure–response relations from two phase II clinical trials
por: Savic, RM, et al.
Publicado: (2017)

Prevalence of neurotoxicity symptoms among postpartum women on isoniazid preventive therapy and efavirenz-based treatment for HIV: an exploratory objective of the IMPAACT P1078 randomized trial
por: Mandima, Patricia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dvc1fn5cnodapi2edpjlnkcu4a